Amedeo Smart

Free Medical Literature Service


 

Amedeo

Leukemia

  Free Subscription

05.02.2024

4 Acta Haematol
3 Ann Hematol
1 Biochem Pharmacol
2 Blood
1 BMC Cancer
1 Cancer Res
2 Eur J Haematol
1 Gene
4 Int J Hematol
1 J Virol
2 Leuk Lymphoma
4 Leuk Res
4 Leukemia
1 PLoS One
1 Proc Natl Acad Sci U S A



    Acta Haematol

  1. AL-SAWAF O
    Importance of Minimal Residual Disease in the Era of Targeted Therapies in Chronic Lymphocytic Leukemia.
    Acta Haematol. 2024;147:22-32.
    >> Share

  2. TADMOR T, Burger J
    Chronic Lymphocytic Leukemia: Novel Perspectives - How to Teach an Old Dog New Tricks.
    Acta Haematol. 2024;147:5-7.
    >> Share

  3. KANG S, Ahn IE
    Prognostic Markers in the Era of Targeted Therapies.
    Acta Haematol. 2024;147:33-46.
    >> Share

  4. GARGIULO E, Teglgaard RS, Faitova T, Niemann CU, et al
    Immune Dysfunction and Infection - Interaction between CLL and Treatment: A Reflection on Current Treatment Paradigms and Unmet Needs.
    Acta Haematol. 2024;147:84-98.
    >> Share


    Ann Hematol

  5. CHEN Y, Pan M, Chen L, Peng M, et al
    Identification of a novel fusion gene, RARA::ANKRD34C, in acute promyelocytic leukemia.
    Ann Hematol. 2024 Jan 31. doi: 10.1007/s00277-024-05629.
    >> Share

  6. CUI J, Zhao M, Liu W, Hong M, et al
    Effect of low skeletal muscle mass on NK cells in patients with acute myeloid leukemia and its correlation with prognosis.
    Ann Hematol. 2024 Jan 31. doi: 10.1007/s00277-024-05645.
    >> Share

  7. LIU Y, Ma Z
    Leukemia and mitophagy: a novel perspective for understanding oncogenesis and resistance.
    Ann Hematol. 2024 Jan 29. doi: 10.1007/s00277-024-05635.
    >> Share


    Biochem Pharmacol

  8. HURRISH KH, Su Y, Patel S, Ramage CL, et al
    Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.
    Biochem Pharmacol. 2024;220:115981.
    >> Share


    Blood

  9. ORDONEZ MAZARIEGOS EE, Dimopoulos YP
    A rare case of ICUS progressing to MDS with isolated isochromosome 17q and AML.
    Blood. 2024;143:473.
    >> Share

  10. ROUSSELOT P
    Old rivals become new friends.
    Blood. 2024;143:380-382.
    >> Share


    BMC Cancer

  11. YAO B, Wang H, Wu X, Wang C, et al
    A system review of central nervous system tumors on children in China: epidemiology and clinical characteristics.
    BMC Cancer. 2024;24:138.
    >> Share


    Cancer Res

  12. MONTEITH AJ, Ramsey HE, Silver AJ, Brown D, et al
    Lactate utilization enables metabolic escape to confer resistance to BET inhibition in acute myeloid leukemia.
    Cancer Res. 2024 Jan 29. doi: 10.1158/0008-5472.CAN-23-0291.
    >> Share


    Eur J Haematol

  13. INFANTE JB, Esteves GV, Raposo J, de Lacerda JF, et al
    Disseminated intravascular coagulation score evolution in 48 h predicts early death in acute promyelocytic leukemia patients.
    Eur J Haematol. 2024 Feb 2. doi: 10.1111/ejh.14177.
    >> Share

  14. WIESEN MHJ, Stemler J, Fietz C, Joisten C, et al
    Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography-tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia.
    Eur J Haematol. 2024 Jan 31. doi: 10.1111/ejh.14178.
    >> Share


    Gene

  15. BASHI MA, Ad'hiah AH
    Molecular landscape of the interleukin-40 encoding gene, C17orf99, in patients with acute myeloid leukemia.
    Gene. 2024;904:148214.
    >> Share


    Int J Hematol

  16. USUKI K, Ohtake S, Honda S, Matsuda M, et al
    Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
    Int J Hematol. 2024;119:130-145.
    >> Share

  17. SCHALK E, Pelz AF
    Auer rods in mature granulocytes in peripheral blood.
    Int J Hematol. 2024;119:105-106.
    >> Share

  18. MARUYAMA D, Omi A, Nomura F, Touma T, et al
    Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance.
    Int J Hematol. 2024;119:146-155.
    >> Share

  19. YANAGI M, Mori M, Honda M, Mitani Y, et al
    Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma.
    Int J Hematol. 2024 Feb 1. doi: 10.1007/s12185-023-03701.
    >> Share


    J Virol

  20. NAGATA K, Tezuka K, Kuramitsu M, Fuchi N, et al
    Establishment of a novel human T-cell leukemia virus type 1 infection model using cell-free virus.
    J Virol. 2024 Jan 31:e0186223. doi: 10.1128/jvi.01862.
    >> Share


    Leuk Lymphoma

  21. LEI MM, Sorial MN, Lou U, Yu M, et al
    Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Leuk Lymphoma. 2024 Jan 31:1-7. doi: 10.1080/10428194.2024.2310144.
    >> Share

  22. NASR AA, Fund X, Barreau S, Desterke C, et al
    BIRC-3 mutated monoclonal B lymphocytosis without evolution to chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2024 Jan 31:1-4. doi: 10.1080/10428194.2024.2308665.
    >> Share


    Leuk Res

  23. BOUCHER L, Rozalska L, Sorel N, Olivier G, et al
    Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation.
    Leuk Res. 2024;137:107439.
    >> Share

  24. OH I, Hatano K, Ikeda T, Toda Y, et al
    Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults.
    Leuk Res. 2024;137:107438.
    >> Share

  25. KUSNE Y, Lasho T, Finke C, Patnaik MM, et al
    VEXAS syndrome in a patient with DDX41 germline predisposition syndrome.
    Leuk Res. 2024;136:107432.
    >> Share

  26. KHANNA V, Lu R, Kumar J, Molina A, et al
    The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
    Leuk Res. 2024;136:107433.
    >> Share


    Leukemia

  27. FRANKHOUSER DE, Rockne RC, Uechi L, Zhao D, et al
    State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia.
    Leukemia. 2024 Feb 2. doi: 10.1038/s41375-024-02142.
    >> Share

  28. DAM M, Centanni M, Friberg LE, Centanni D, et al
    Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia.
    Leukemia. 2024 Jan 29. doi: 10.1038/s41375-024-02153.
    >> Share

  29. JABBOUR E, Apperley J, Cortes J, Rea D, et al
    Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
    Leukemia. 2024 Jan 29. doi: 10.1038/s41375-024-02159.
    >> Share

  30. FLYGT H, Soderlund S, Richter J, Saussele S, et al
    Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
    Leukemia. 2024 Jan 26. doi: 10.1038/s41375-024-02145.
    >> Share


    PLoS One

  31. HUANG T, Leung B, Huang Y, Price L, et al
    A murine model to evaluate immunotherapy effectiveness for human Fanconi anemia-mutated acute myeloid leukemia.
    PLoS One. 2024;19:e0292375.
    >> Share


    Proc Natl Acad Sci U S A

  32. MOTTAGHINIA S, Stenzel S, Tsangaras K, Nikolaidis N, et al
    A recent gibbon ape leukemia virus germline integration in a rodent from New Guinea.
    Proc Natl Acad Sci U S A. 2024;121:e2220392121.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016